{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:05:14Z","timestamp":1794049514183,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clgc.2026.102519","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:33:55Z","timestamp":1770770035000},"page":"102519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment Patterns Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer: A Global Real-World Study"],"prefix":"10.1016","volume":"24","author":[{"given":"Gunhild","family":"von Amsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Bulkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5486-5584","authenticated-orcid":false,"given":"Marc","family":"DeCongelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-7356","authenticated-orcid":false,"given":"Grace","family":"Skiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Grisolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-6050","authenticated-orcid":false,"given":"Nihar","family":"Masurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6841-2292","authenticated-orcid":false,"given":"Cecile","family":"Morasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1006-7941","authenticated-orcid":false,"given":"Sophia","family":"Costanza-McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4441-4585","authenticated-orcid":false,"given":"Xin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7378-1675","authenticated-orcid":false,"given":"Siguroli","family":"Teitsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-1420","authenticated-orcid":false,"given":"Miraj Y.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-738X","authenticated-orcid":false,"given":"Vivek","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102519_bib0001","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clgc.2026.102519_bib0002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102519_bib0003","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102519_bib0004","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2026.102519_bib0005","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102519_bib0006","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102519_bib0007","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102519_bib0008","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102519_bib0009","unstructured":"CMP: CancerMPact\u00ae patient metrics, oracle life sciences. Available at: www.cancermpact.com. Accessed: August 7, 2024."},{"key":"10.1016\/j.clgc.2026.102519_bib0010","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2217\/fon-2023-0814","article-title":"Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia","volume":"20","author":"Goebell","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.clgc.2026.102519_bib0011","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s12325-022-02073-w","article-title":"Real-world treatment patterns in metastatic castration-resistant prostate cancer across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan","volume":"39","author":"Leith","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.clgc.2026.102519_bib0012","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/oncolo\/oyad045","article-title":"Real-world treatment trends among patients with metastatic castration-sensitive prostate cancer: results from an international study","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2026.102519_bib0013","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.euros.2022.08.018","article-title":"Real-world treatment sequencing in patients with metastatic castration-resistant prostate cancer: results from the prospective, international, observational prostate cancer registry","volume":"45","author":"Bjartell","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2026.102519_bib0014","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","article-title":"Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the prostate cancer registry","volume":"15","author":"Chowdhury","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.clgc.2026.102519_bib0015","unstructured":"XTANDI (enzalutamide) capsules for oral use [prescribing information]: United States Food and Drug Administration (2019). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203415s015lbl.pdf. Accessed: August 7, 2024."},{"key":"10.1016\/j.clgc.2026.102519_bib0016","unstructured":"ZYTIGA (abiraterone acetate) tablets for oral use [prescribing information]: United States Food and Drug Administration (2020). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202379s031s033lbl.pdf. Accessed: August 7, 2024."},{"key":"10.1016\/j.clgc.2026.102519_bib0017","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102519_bib0018","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bju.14152","article-title":"Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer","volume":"121","author":"Sonpavde","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102519_bib0019","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.euf.2016.10.008","article-title":"Optimal treatment sequence for metastatic castration-resistant prostate cancer","volume":"2","author":"Lorente","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102519_bib0020","unstructured":"Network, N.C.C., NCCN Guidelines Version 4.2024 prostate cancer (2024). Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459. Accessed: August 7, 2024."},{"key":"10.1016\/j.clgc.2026.102519_bib0021","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/bco2.129","article-title":"Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer","volume":"3","author":"Anton","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.clgc.2026.102519_bib0022","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2026.102519_bib0023","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2217\/fon-2021-1096","article-title":"A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer","volume":"18","author":"Agarwal","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2026.102519_bib0024","doi-asserted-by":"crossref","unstructured":"Sartor O, Jiang DM, Smoragiewicz M, et al. Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). Poster presented at: ESMO Congress; September 15; 2024. Barcelona, Spain.","DOI":"10.1016\/j.annonc.2024.08.2308"},{"key":"10.1016\/j.clgc.2026.102519_bib0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cam4.576","article-title":"Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data","volume":"5","author":"Flaig","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.clgc.2026.102519_bib0026","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/14737167.2017.1300530","article-title":"The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use","volume":"17","author":"Uemura","year":"2017","journal-title":"Expert Rev Pharmacoeconomic Outcomes Res"},{"key":"10.1016\/j.clgc.2026.102519_bib0027","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:42:40Z","timestamp":1776102160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1558767326000194"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102519","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer: A Global Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102519"}}